Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …

Background Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a
recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (…

Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …

Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …

Background Concerns have been raised regarding a potential surge of COVID-19 in
pregnancy, secondary to the rising numbers of COVID-19 in the community, easing of societal …

Background Given the importance of flexible use of different COVID-19 vaccines within the
same schedule to facilitate rapid deployment, we studied mixed priming schedules …

Background Despite widespread use of intrapartum antibiotic prophylaxis, group B streptococcus
remains a leading cause of morbidity and mortality in infants in Europe, the Americas, …

Introduction Neonatal infection is an important cause of morbidity and mortality. Neonatal
infection surveillance networks are necessary for defining the epidemiology of infections and …

Background COVID-19 vaccine supply shortages are causing concerns about compromised
immunity in some countries as the interval between the first and second dose becomes …

Background We aimed to provide the first comprehensive estimates of the burden of group B
Streptococcus (GBS), including invasive disease in pregnant and postpartum women, fetal …